Additionally, in human breast cancer cells, silencing CD44 was also shown to decrease the glycolytic phenotype of cancer cells via regulating c‐Src/AKT/LKB1/AMPKα/HIF‐1α signaling.239. This evidence concerns the gene CD44 and cancer.